249 related articles for article (PubMed ID: 8339418)
1. Transdermal modification of platelet function. A dermal aspirin preparation selectively inhibits platelet cyclooxygenase and preserves prostacyclin biosynthesis.
Keimowitz RM; Pulvermacher G; Mayo G; Fitzgerald DJ
Circulation; 1993 Aug; 88(2):556-61. PubMed ID: 8339418
[TBL] [Abstract][Full Text] [Related]
2. Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects.
Capone ML; Tacconelli S; Sciulli MG; Grana M; Ricciotti E; Minuz P; Di Gregorio P; Merciaro G; Patrono C; Patrignani P
Circulation; 2004 Mar; 109(12):1468-71. PubMed ID: 15037526
[TBL] [Abstract][Full Text] [Related]
3. Urinary excretion of thromboxane and prostacyclin metabolites during chronic low-dose aspirin: evidence for an extrarenal origin of urinary thromboxane B2 and 6-keto-prostaglandin F1 alpha in healthy subjects.
Chiabrando C; Rivoltella L; Martelli L; Valzacchi S; Fanelli R
Biochim Biophys Acta; 1992 Feb; 1133(3):247-54. PubMed ID: 1737057
[TBL] [Abstract][Full Text] [Related]
4. Suppression of thromboxane A2 but not of systemic prostacyclin by controlled-release aspirin.
Clarke RJ; Mayo G; Price P; FitzGerald GA
N Engl J Med; 1991 Oct; 325(16):1137-41. PubMed ID: 1891022
[TBL] [Abstract][Full Text] [Related]
5. Transdermal modification of platelet function: an aspirin patch system results in marked suppression of platelet cyclooxygenase.
McAdam B; Keimowitz RM; Maher M; Fitzgerald DJ
J Pharmacol Exp Ther; 1996 May; 277(2):559-64. PubMed ID: 8627531
[TBL] [Abstract][Full Text] [Related]
6. Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man.
FitzGerald GA; Oates JA; Hawiger J; Maas RL; Roberts LJ; Lawson JA; Brash AR
J Clin Invest; 1983 Mar; 71(3):676-88. PubMed ID: 6338043
[TBL] [Abstract][Full Text] [Related]
7. Clinical pharmacology of platelet cyclooxygenase inhibition.
Patrono C; Ciabattoni G; Patrignani P; Pugliese F; Filabozzi P; Catella F; Davì G; Forni L
Circulation; 1985 Dec; 72(6):1177-84. PubMed ID: 3933848
[TBL] [Abstract][Full Text] [Related]
8. Differential inhibition by aspirin of platelet thromboxane and renal prostaglandins in the rat.
Livio M; Benigni A; Zoja C; Begnis R; Morelli C; Rossini M; Garattini S; Remuzzi G
J Pharmacol Exp Ther; 1989 Jan; 248(1):334-41. PubMed ID: 2492341
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of prostacyclin and thromboxane A2 generation by low-dose aspirin at the site of plug formation in man in vivo.
Kyrle PA; Eichler HG; Jäger U; Lechner K
Circulation; 1987 May; 75(5):1025-9. PubMed ID: 3552295
[TBL] [Abstract][Full Text] [Related]
10. Differential effect of aspirin on thromboxane and prostaglandin biosynthesis in man.
Ritter JM; Cockcroft JR; Doktor HS; Beacham J; Barrow SE
Br J Clin Pharmacol; 1989 Nov; 28(5):573-9. PubMed ID: 2590611
[TBL] [Abstract][Full Text] [Related]
11. Selective and nonselective inhibition of thromboxane formation.
FitzGerald GA; Oates JA
Clin Pharmacol Ther; 1984 May; 35(5):633-40. PubMed ID: 6370554
[TBL] [Abstract][Full Text] [Related]
12. Human pharmacology of naproxen sodium.
Capone ML; Tacconelli S; Sciulli MG; Anzellotti P; Di Francesco L; Merciaro G; Di Gregorio P; Patrignani P
J Pharmacol Exp Ther; 2007 Aug; 322(2):453-60. PubMed ID: 17473175
[TBL] [Abstract][Full Text] [Related]
13. Increased prostacyclin production during exercise in untrained and trained men: effect of low-dose aspirin.
Böger RH; Bode-Böger SM; Schröder EP; Tsikas D; Frölich JC
J Appl Physiol (1985); 1995 May; 78(5):1832-8. PubMed ID: 7649919
[TBL] [Abstract][Full Text] [Related]
14. A prostacyclin-sparing effect of indobufen vs. aspirin.
De Caterina R; Giannessi D; Bernini W; Lazzerini G; Lavezzari M; Stragliotto E; Biagi G; Coccheri S
Thromb Haemost; 1996 Mar; 75(3):510-4. PubMed ID: 8701417
[TBL] [Abstract][Full Text] [Related]
15. Effects of salicylic and acetylsalicylic acid alone and in combination on platelet aggregation and prostanoid synthesis in man.
Rosenkranz B; Fischer C; Meese CO; Frölich JC
Br J Clin Pharmacol; 1986 Mar; 21(3):309-17. PubMed ID: 3083851
[TBL] [Abstract][Full Text] [Related]
16. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2.
McAdam BF; Catella-Lawson F; Mardini IA; Kapoor S; Lawson JA; FitzGerald GA
Proc Natl Acad Sci U S A; 1999 Jan; 96(1):272-7. PubMed ID: 9874808
[TBL] [Abstract][Full Text] [Related]
17. Effects of very low dose and enteric-coated acetylsalicylic acid on prostacyclin and thromboxane formation and on bleeding time in healthy subjects.
Bode-Böger SM; Böger RH; Schubert M; Frölich JC
Eur J Clin Pharmacol; 1998; 54(9-10):707-14. PubMed ID: 9923572
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs.
Reilly IA; FitzGerald GA
Blood; 1987 Jan; 69(1):180-6. PubMed ID: 3790723
[TBL] [Abstract][Full Text] [Related]
19. Vascular thromboxane formation in hemostasis mechanism: correlation between bleeding time and vascular TXB2 in a patient with congenital platelet cyclo-oxygenase deficiency.
Fuse I; Ootsuka T; Hattori A; Mito M; Shibata A
Int J Hematol; 1996 Jun; 63(4):317-24. PubMed ID: 8762815
[TBL] [Abstract][Full Text] [Related]
20. Thromboxane A2 and prostacyclin generation in the microvasculature of patients with atherosclerosis--effect of low-dose aspirin.
Kyrle PA; Minar E; Brenner B; Eichler HG; Heistinger M; Marosi L; Lechner K
Thromb Haemost; 1989 Jun; 61(3):374-7. PubMed ID: 2508252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
